Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arbutus Biopharma ( (ABUS) ) has issued an update.
On October 7, 2025, Arbutus Biopharma announced that four abstracts featuring data on their products imdusiran and AB-101 were accepted for presentation at the American Association for the Study of Liver Diseases – The Liver Meeting 2025. The AB-101 abstract was notably selected as a Poster of Distinction. These presentations highlight the safety and potential efficacy of imdusiran in enhancing treatment responses in chronic hepatitis B patients and the promising pharmacodynamics of AB-101, which may strengthen Arbutus’s position in the biopharmaceutical industry focused on infectious diseases.
The most recent analyst rating on (ABUS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma’s overall score is driven by significant financial challenges, despite positive corporate events and moderate technical momentum. The company’s negative profitability and cash flow issues weigh heavily, while recent board changes and litigation prospects offer potential upside.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B virus (cHBV) infection. The company is developing RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) as potential treatments for cHBV.
Average Trading Volume: 1,049,191
Technical Sentiment Signal: Strong Buy
Current Market Cap: $832M
Learn more about ABUS stock on TipRanks’ Stock Analysis page.